TY - JOUR
T1 - Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction
AU - Park, Kyung Woo
AU - Lim, Woo Hyun
AU - Kim, Ji Hyun
AU - Kang, Si Hyuck
AU - Seo, Jung Won
AU - Song, Young Bin
AU - Hahn, Joo Yong
AU - Lee, Hae Young
AU - Kang, Hyun Jae
AU - Cho, Young Seok
AU - Youn, Tae Jin
AU - Koo, Bon Kwon
AU - Choi, Seung Hyuk
AU - Chae, In Ho
AU - Gwon, Hyeon Cheol
AU - Choi, Dong Ju
AU - Kim, Hyo Soo
PY - 2013/6/5
Y1 - 2013/6/5
N2 - Background: The purpose of this study was to compare the two year efficacy and safety of zotarolimus-eluting stents (ZES) and first-generation DES, sirolimus- (SES) and paclitaxel-eluting stents (PES), in an all-comer registry receiving primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI). Methods: A total of 711 consecutive STEMI patients (ZES: 135, SES: 427, and PES: 149), who underwent primary PCI between January 2005 and June 2008 were enrolled from three centers. In our study, the efficacy analysis endpoint was target vessel failure (cardiac death, target vessel related myocardial infarction, and ischemia-driven target vessel revascularization) at 2 years. The safety analysis endpoint was a composite of all cause death, non-fatal myocardial infarction, and stent thrombosis within 2 years. Results: At 2 years, the rates of target vessel failure in the ZES, SES, and PES groups were 14.8%, 12.9%, and 19.5%, respectively (p = 0.141). The rates of composite safety endpoints at 2 years were not different among the three groups (ZES 8.1% vs. SES 13.1% vs. PES 16.8%, p = 0.102). However, when comparing the two groups, ZES was safer than PES (adjusted HR 0.48, 95% CI 0.24-0.98, p = 0.046). There was also a non-significant trend in favor of ZES in the rate of stent thrombosis (ZES 1.5% vs. SES 2.3% vs. PES 4.7%, p = 0.186). Conclusion: In the treatment of STEMI patients, ZES showed similar and acceptable efficacy compared to first-generation DES (SES and PES) up to 2 years. In addition, ZES seems to be more favorable than PES in terms of safety.
AB - Background: The purpose of this study was to compare the two year efficacy and safety of zotarolimus-eluting stents (ZES) and first-generation DES, sirolimus- (SES) and paclitaxel-eluting stents (PES), in an all-comer registry receiving primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI). Methods: A total of 711 consecutive STEMI patients (ZES: 135, SES: 427, and PES: 149), who underwent primary PCI between January 2005 and June 2008 were enrolled from three centers. In our study, the efficacy analysis endpoint was target vessel failure (cardiac death, target vessel related myocardial infarction, and ischemia-driven target vessel revascularization) at 2 years. The safety analysis endpoint was a composite of all cause death, non-fatal myocardial infarction, and stent thrombosis within 2 years. Results: At 2 years, the rates of target vessel failure in the ZES, SES, and PES groups were 14.8%, 12.9%, and 19.5%, respectively (p = 0.141). The rates of composite safety endpoints at 2 years were not different among the three groups (ZES 8.1% vs. SES 13.1% vs. PES 16.8%, p = 0.102). However, when comparing the two groups, ZES was safer than PES (adjusted HR 0.48, 95% CI 0.24-0.98, p = 0.046). There was also a non-significant trend in favor of ZES in the rate of stent thrombosis (ZES 1.5% vs. SES 2.3% vs. PES 4.7%, p = 0.186). Conclusion: In the treatment of STEMI patients, ZES showed similar and acceptable efficacy compared to first-generation DES (SES and PES) up to 2 years. In addition, ZES seems to be more favorable than PES in terms of safety.
KW - Drug-eluting stent
KW - Paclitaxel-eluting stent
KW - ST-elevation myocardial infarction
KW - Sirolimus-eluting stent
KW - Zotarolimus-eluting stent
UR - http://www.scopus.com/inward/record.url?scp=84877732642&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2011.10.012
DO - 10.1016/j.ijcard.2011.10.012
M3 - Article
C2 - 22062892
AN - SCOPUS:84877732642
SN - 0167-5273
VL - 166
SP - 118
EP - 125
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 1
ER -